*The CHMP has issued a positive opinion for rozanolixizumab. If approved in Q1 2024, the drug will be the first anti-FcRn approved in Europe for both anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive gMG, the two most common subtypes of gMG.*In addition, UCB released the results from a post-hoc analysis indication meaningful efficacy of CIMZIA® in rheumatoid arthritis (RA) patients with high rheumatoid factor (RF) levels.*No impact on estimates and investment case. Buy rating reiterating considering the upside to Friday's closing price (>50%). We consider the market reaction to BIMZELX® 's approval overdone: ramp-up will take time as
